Navigation Links
Researchers use 'trickery' to create immune response against melanoma

Ground-breaking results from researchers at Harvard Medical School and Massachusetts Institute of Technology (MIT), USA, disclosed at the 13th European Cancer Conference (ECCO) have shown for the first time that targeted drug delivery is possible using nanoparticle-apatamer conjugates.

Nucleic acid ligands (referred to as aptamers) are short DNA or RNA fragments that can bind to target antigens with high specificity and affinity; analogous to monoclonal antibodies. In the field of cancer nanotechnology, aptamers have the potential to act as targeting molecules - directing the delivery of nanoparticles to tumour-antigens, present on the surface of cancer cells. In general terms, therapeutic nanoparticles (~50 ?~250 nanometer) are specially designed delivery vehicles that can encapsulate a drug within them and release the drug in a pre-determined and regulated manner which can vary from a sudden release to a slow release over a period of several years. Using prostate cancer as a model disease, proof of concept nanoscale targeted drug delivery vehicles were developed (1 nanometer = 0.000000001 meter), which can target prostate cancer cells with high specificity and efficiency. Once bound to prostate cancer cells, the nanoparticle/aptamer bioconjugates were internalised making it possible for their cytotoxic payload to get released directly inside the cancer cells. The combination of targeted delivery and controlled release of drugs at the site of cancer will likely result in "smart therapeutics" that are more effective, yet safer than what is available today.

As the initial step, researchers synthesised nanoparticles for controlled drug release made from a biocompatible and biodegradable PLA polymer system and encapsulated a fluorescently labeled model drug within them, in order to visualise nanoparticle uptake into target cells. The nanoparticles in question were designed for attachment to aptamers so that the binding properties of aptamers for targeti
'"/>

Source:University of Pittsburgh Medical Center


Page: 1 2 3 4

Related biology news :

1. Researchers discover way to make cells in the eye sensitive to light
2. Researchers find how protein allows insects to detect and respond to pheromones
3. Researchers Uncover Key Step In Manufacture of Memory Protein
4. Researchers reveal the infectious impact of salmon farms on wild salmon
5. Researchers identify target for cancer drugs
6. Researchers discover molecule that causes secondary stroke
7. Researchers find missing genes of ancient organism
8. Researchers trace evolution to relatively simple genetic changes
9. Researchers add new tool to tumor-treatment arsenal
10. UF Researchers Map Bacterial Proteins That Cause Tooth Loss
11. VCU Researchers Identify Networks Of Genes Responding To Alcohol In The Brain
Post Your Comments:
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... at Northwestern University Feinberg School of Medicine played ... approval of Abraxane (paclitaxel protein-bound particles for injectable ... cancer. "The approval means that women with metastatic ... toxicities associated with solvents and will no longer ...
... Hopkins Medical Institutions in Baltimore, Md., reports that whole-body ... identify new, unexpected malignant cancerous tumors in patients, according ... Society of Nuclear Medicine's Journal of Nuclear Medicine. , ... to have cancer," said SNM member Richard L. Wahl, ...
... and Drug Administration (FDA) was "the single greatest obstacle ... safety officer David Graham at an unprecedented roundtable of ... (PLoS) and the Government Accountability Project. , In comments ... Senate Finance Committee, Graham said that, "Nearly 60,000 people ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2Medical whistleblowers speak out 2Medical whistleblowers speak out 3
(Date:2/27/2015)... and SUMMERLAND, British Columbia , Feb. ... XON ), a leader in synthetic biology, today ... Okanagan Specialty Fruits (OSF), the pioneering agricultural company ... world,s first non-browning apple. Through the acquisition, Intrexon expands ... is more appetizing and convenient for consumers while providing ...
(Date:2/27/2015)... 27, 2015 A paper published today, ... portfolio " in Science Translational Medicine, ... to reduce the risk associated with investing in ... new levels of funding for developing so-called "orphan" ... unique collaboration between scientists at the National Center ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY) is to present ... in patients with metastatic renal cancer at the ASCO ... . The data will be presented by Dr. ... Cancer Center in California in ... identifies Ferritin and IL-8 as two baseline biomarkers that ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5
... Switzerland, Aug. 21 Roche (SWX: ROG.VX; RO.S),a world-leading ... has extended its offer to acquire all of the,outstanding ... VMSI ),to 5:00 p.m., New York City time on ... to expire at 5:00 p.m., New York City,time, on ...
... and PRAGUE, Czech Republic, Aug. 21 ... organization, today,announced it has completed the acquisition ... (CRO) headquartered in Prague, Czech,Republic. This move ... and,expands its capacity to provide full service ...
... WOODLANDS, Texas, Aug. 21 ,Lexicon Pharmaceuticals, Inc. ... the structure-activity relationship (SAR) of a class ... compounds,under evaluation by the company as potential ... gastrointestinal disorders. LX1031 is currently,under evaluation in ...
Cached Biology Technology:Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Medpace Strengthens Presence in Central Europe 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... Reverse Transcriptase (AMV RT) catalyzes the polymerization ... RNA:DNA hybrids (1). It requires a primer ... primers) as well as Mg2+ or Mn2+. ... activity. Both nonionic detergents and sulfhydryl compounds ...
... Stem Cell Expansion Kit - Neurosphere is a ... stem cell expansion as neurospheres in a serum ... N-2 Plus Media Supplement, which has been optimized ... et al . (1996) Genes & Development ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
Biology Products: